Immune checkpoint inhibitors involving anti-programmed cell death protein 1 (PD-1), PD-L1, and cytotoxic T-lymphocyte associated protein 4 (CTLA4) antibodies are being investigated in AML [25,26]. The gene discussed is PDCD1; the disease is acute myeloid leukemia.